محاسبه توزیع دز در پروتون درمانی سرطان معده به روش مونت کارلو

نویسندگان

دانشگاه دامغان

10.22052/6.4.19

چکیده

پروتون درمانی که شکلی رایج از پرتودرمانی خارجی است و مبتنی بر دست­کاری قله براگ این پرتو می­باشد، می­ تواند به‌وسیله تحویل سطوح بالایی از دز به تومور، درحالی­که بافت­ های سالم اطراف را از تابش محفوظ نگه می­دارد، آن را درمان کند. در این کار توزیع دز پروتون و ذرات ثانویه­ ای چون نوترون، فوتون، الکترون و پوزیترون در پروتون­ درمانی سرطان معده مورد مطالعه قرار گرفته است. به همین منظور با به ­کارگیری باریکه تک انرژی پروتون، بازه انرژی مناسب جهت درمان تومور در بافت معده یک فانتوم مرد بزرگ­سال MIRD-UF محاسبه شده و سپس با استفاده از نتایج دزیمتری به ساختن SOBP < /span> مربوط به روش ماتریسی پرداخته شده است. همچنین دز اولیه و ثانویه در 12 ارگان سالم اطراف مورد بررسی قرار گرفت که نتایج نشان می­دهد دز اولیه در ارگان­ های سالم نسبت به دز دریافتی تومور بسیار کوچک­تر است. دز ثانویه گرچه اندک است اما میزان آن درون معده، طحال، لوزالمعده و کلیه چپ نسبت به سایر ارگان­ ها بیش­تر به­ دست آمد. نتایج بررسی ­ها نشان می­ دهد، پروتون درمانی سرطان معده با تعیین میزان خطرات ناشی از دز ذرات ثانویه به­ ویژه دز معادل نوترون، می­تواند یک پرتودرمانی تقریباً ایده ­آل را به نمایش بگذارد.
 

کلیدواژه‌ها

عنوان مقاله [English]

Monte Carlo calculations of dose distribution for the treatment of gastric cancer with proton therapy

نویسندگان [English]

  • sara sdrzadeh
  • mojtaba tajik
چکیده [English]

Proton therapy is a common form of external radiation therapy based on the manipulation of Bragg peak of this beam, it can treat the tumor by delivering high levels of doses to it, while protecting surrounding healthy tissues against radiation. In this work, the dose distribution of proton and secondary particles such as neutrons, photons, electrons and positrons in gastric cancer proton therapy have been studied. For this purpose, using a single-energy proton beam, the suitable energy range has been calculated for treating a tumor in the gastric tissue of a male adult male MRD-UF phantom. Then, the SOBP of the matrix method has been constructed using the dosimetry results. The primary and secondary doses were also examined in 12 surrounding healthy organs. The results show that the primary dose in healthy organs is much smaller than the dose received by the tumor. Although the secondary dose is small, but its amount in the stomach, spleen, pancreas and left kidney is higher than those in other organs. The results of the study show that the proton therapy of gastric cancer can represent an almost ideal radiation therapy by measuring the risk levels of secondary particle dose, in particular, the equivalent dose of neutrons.
 
 

کلیدواژه‌ها [English]

  • Proton therapy
  • Bragg peak
  • Gastric cancer
  • MIRD-UF phantom
  • SOBP

مراجع

[1]D. Schardt, T. Elsässer, D. Schulz-Ertner, Heavy-ion tumor therapy: physical and radiobiological benefits, Reviews of modern physics, 82 (2010) 383. [2] H. Paganetti, Proton Therapy Physics, CRC Press (2016). [3] R. Mohan, D. Grosshans, Proton therapy – Present and future, Advanced Drug Delivery Reviews, 109 (2017) 26–44. [4] M.T. Gillin, N. Sahoo, M. Bues, G. Ciangaru, G. Sawakuchi, F. Poenisch, B. Arjomandy, C. Martin, U. Titt and K. Suzuki. Commissioning of the discrete spot scanning proton beam delivery system at the University of Texas MD Anderson Cancer Center, Proton Therapy Center, Houston, Medical physics, 37 (2010) 154–163. [5] F. Dionisi, S. Avery, J.N. Lukens, X. Ding, J. Kralik, M. Kirk, R.E. Roses, M. Amichetti, J.M. Metz and J.P. Plastaras. Proton therapy in adjuvant treatment of gastric cancer: planning comparison with advanced x-ray therapy and feasibility report, Acta Oncologica, 53(10) (2014) 1312–1320. [6] T.C. Ling, J.I. Kang, J.D. Slater and G.Y. Yang. Proton therapy for gastrointestinal cancers, Translational Cancer Research, 1(3) (2012) 150–158. [7] S. Koyama, N. Kawanishi, H. Fukutomi, T. Osuga, T. Iijima, H. Tsujii and T. Kitagawa. Advanced carcinoma of the stomach treated with definitive proton therapy, American Journal of Gastroenterology, 85(4) (1990) 443–447. [8] S. Shibuya, Y. Takase, H. Aoyagi, K. Orii, N. Sharma, H. Tsujii, H. Tsuji and Y. Iwasaki. Definitive proton beam radiation therapy for inoperable gastric cancer: a report of two cases, Radiation medicine, 9 (1990) 35–40. [9] J.P. Plastaras, F. Dionisi and J.Y. Wo. Gastrointestinal cancer: Nonliver proton therapy for gastrointestinal cancers, The Cancer Journal, 20 (2014) 378–386. [10] V. Verma, S.H. Lin and C.B. Simone. Clinical outcomes and toxicities of proton radiotherapy for gastrointestinal neoplasms: a systematic review, Journal of gastrointestinal oncology, 7 (2016) 644. [11] D.C. Weber, C. Ares, A.J. Lomax and J.M. Kurtz. Radiation therapy planning with photons and protons for early and advanced breast cancer: an overview, Radiation Oncology, 1 (2006) 22. [12] S. Agosteo, C. Birattari, M. Caravaggio, M. Silari and G. Tosi. Secondary neutron and photon dose in proton therapy, Radiotherapy and Oncology, 48 (1998) 293–305. [13] U. Schneider, S. Agosteo, E. Pedroni and J. Besserer. Secondary neutron dose during proton therapy using spot scanning, International Journal of Radiation Oncology* Biology* Physics, 53 (2002) 244–251. [14] B. Dent and S.M. Griffin. Gastric tumours, Surgery (Oxford), 32 (2014) 608–613. [15] W.J. Im, M.G. Kim, T.K. Ha and S.J. Kwon. Tumor size as a prognostic factor in gastric cancer patient, Journal of gastric cancer, 12 (2012) 164–172. [16] R.L. Maughan, P. Chuba, A.T. Porter, E. Ben‐Josef, D.R. Lucas and B.E. Bjarngard. Mass energy‐absorption coefficients and mass collision stopping powers for electrons in tumors of various histologies, Medical Physics, 26 (1999) 472–477. [17] M.J. Berger. Penetration of Proton Beams Through Water: Depth-dose Distribution, Spectra and LET Distributions, National Institute of Standards and Technology (1993). [18] A.R.Z. Wayne D Newhauser, The physics of proton therapy, DOI (2015). [19] Y. Zheng, W. Newhauser, J. Fontenot, P. Taddei and R. Mohan. Monte Carlo study of neutron dose equivalent during passive scattering proton therapy, Physics in medicine and biology, 52 (2007) 4481. [20] P. Dyer, D. Bodansky, A.G. Seamster, E.B. Norman and D.R. Maxson. Cross sections relevant to gamma-ray astronomy: Proton induced reactions, Physical Review C, 23 (1981) 1865–1882. [21] S. Raman, E. Jurney, J. Starner, A. Kuronen, J. Keinonen, K. Nordlund and D. Millener. Lifetimes in N 15 from gamma-ray line shapes produced in the H 2 (14 N, pγ) and N 14 (thermal n, γ) reactions, Physical Review C, 50 (1994) 682. [22] T.N. Taddeucci, R.R. Doering, A. Galonsky and S.M. Austin. (p,n) reactions on 14C and 14N and the effective nucleon-nucleon interaction, Physical Review C, 29 (1984) 764–776. [23] W.W. Eidson and R.D. Bent. Gamma Decay of the 7.57-MeV Level of N15, Physical Review, 127 (1962) 913–916. [24] S.R. Kane. Solar Gamma-, X-, and EUV Radiation, Springer Netherlands (2012). [25] W.D. Newhauser, J.D. Fontenot, A. Mahajan, D. Kornguth, M. Stovall, Y. Zheng, P.J. Taddei, D. Mirkovic, R. Mohan and J.D. Cox. The risk of developing a second cancer after receiving craniospinal proton irradiation, Physics in Medicine & Biology, 54 (2009) 2277.

فایل ها

هم رسانی

ارجاع به این مقاله

آمار